Myelodysplastic syndrome (MDS) is a blood cancer that usually begins with symptoms of anaemia (low numbers of red blood cells). This can progress over time to a more severe illness and eventually leukaemia. Most patients with NDS die from leukaemia of infections as a result of the disease. The only curative treatment for MDS is a bone marrow transplant. However, bone marrow transplants require a suitable donor and are often associated with severe side effects, making this treatment unsuitable for many patients.
The only cure for MDS is a stem cell transplant. However, as most
patients are already in their 60’s or older, there is significant toxicity from
the procedure and a lower likelihood that their siblings will be fit enough to
donate if matched. Furthermore, 5 years later, only around a third of patients
who receive a transplant will be alive and free from disease. Thus, new less
toxic therapies are desperately needed to treat MDS and delay or prevent
progression to leukaemia. This funding award has come at a particularly
critical time for me as I make the transition to fully independent
investigator, while balancing my MDS clinical practice as Consultant
Haematologist at UCLH – and looking after my young family. Obtaining funding is
a particular challenge for young researchers as they are viewed as more 'risky' than established researchers. Investing in the next generation of leukaemia
researchers is absolutely critical to permit continuing high quality research
into curing leukaemia and related disorders.
Leuka's funding will allow me to develop new models of MDS that can be used to test new drugs. We already have some promising results and hope that our findings can reall have an impact on patients' lives.Dr Beth Payne